Arcus Enterprise Value Over E B I T D A from 2010 to 2025
| RCUS Stock | USD 20.19 0.10 0.49% |
Enterprise Value Over EBITDA | First Reported 2010-12-31 | Previous Quarter (5.02) | Current Value (4.77) | Quarterly Volatility 16.79957199 |
Check Arcus Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Arcus Biosciences' main balance sheet or income statement drivers, such as Net Interest Income of 50.4 M, Interest Income of 54.6 M or Depreciation And Amortization of 5.2 M, as well as many indicators such as Price To Sales Ratio of 4.94, Dividend Yield of 0.0 or PTB Ratio of 3.11. Arcus financial statements analysis is a perfect complement when working with Arcus Biosciences Valuation or Volatility modules.
Arcus | Enterprise Value Over E B I T D A | Build AI portfolio with Arcus Stock |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arcus Stock Analysis
When running Arcus Biosciences' price analysis, check to measure Arcus Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcus Biosciences is operating at the current time. Most of Arcus Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcus Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcus Biosciences' price. Additionally, you may evaluate how the addition of Arcus Biosciences to your portfolios can decrease your overall portfolio volatility.